A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
revised:
17
05
2024
received:
15
03
2024
accepted:
23
05
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) events are currently available. We aimed to compare the risk of achieving first 6 months confirmed PIRA and RAW events and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 in a cohort of naïve patients treated with natalizumab or ocrelizumab from the Italian Multiple Sclerosis Register. Patients with a first visit within 1 year from onset, treated with natalizumab or ocrelizumab, and ≥3 visits were extracted. Pairwise propensity score-matched analyses were performed. Risk of reaching the first PIRA, RAW, and EDSS 4.0 and 6.0 events were estimated using multivariable Cox proportional hazards models. Kaplan-Meier curves were used to show cumulative probabilities of reaching outcomes. In total, 770 subjects were included (natalizumab = 568; ocrelizumab = 212) and the propensity score-matching retrieved 195 pairs. No RAW events were found in natalizumab group and only 1 was reported in ocrelizumab group. A first PIRA event was reached by 23 natalizumab and 25 ocrelizumab exposed patients; 7 natalizumab- and 10 ocrelizumab-treated patients obtained an irreversible EDSS 4.0, while 13 natalizumab- and 15 ocrelizumab-treated patients reached an irreversible EDSS 6.0. No differences between the two groups were found in the risk (HR, 95%CI) of reaching a first PIRA (1.04, 0.59-1.84; p = 0.88) event, an irreversible EDSS 4.0 (1.23, 0.57-2.66; p = 0.60) and 6.0 (0.93, 0.32-2.68; p = 0.89). Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147‐3161.
Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real‐life cohort study. Brain. 2022;145(8):2796‐2805.
University of California, San Francisco MS‐EPIC Team, Cree BAC, Hollenbach JA, et al. Silent progression in disease activity‐free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653‐666.
Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse‐independent progression vs relapse‐associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132‐1140.
Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380‐1390.e2.
Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord. 2022;15:17562864211066751.
Jokubaitis VG, Spelman T, Kalincik T, et al. Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis. Ann Neurol. 2016;80(1):89‐100.
Koch‐Henriksen N, Sørensen PS, Magyari M. Relapses add to permanent disability in relapsing multiple sclerosis patients. Mult Scler Relat Disord. 2021;53:103029.
Iaffaldano P, Portaccio E, Lucisano G, et al. Multiple sclerosis progression and relapse activity in children [published correction appears in JAMA Neurol. 2024;81(1):88]. JAMA Neurol. 2024;81(1):50‐58.
Tur C, Kalincik T, Oh J, et al. Head‐to‐head drug comparisons in multiple sclerosis: urgent action needed. Neurology. 2019;93(18):793‐809.
Filippi M, Amato MP, Centonze D, et al. Early use of high‐efficacy disease‐modifying therapies makes the difference in people with multiple sclerosis: an expert opinion [published correction appears in J Neurol. 2022;269(12):6690‐6691]. J Neurol. 2022;269(10):5382‐5394.
Trojano M, Kalincik T, Iaffaldano P, Amato MP. Interrogating large multiple sclerosis registries and databases: what information can be gained? Curr Opin Neurol. 2022;35(3):271‐277.
Trojano M, Bergamaschi R, Amato MP, et al. The Italian multiple sclerosis register [published correction appears in Neurol Sci. 2019;40(4):907]. Neurol Sci. 2019;40(1):155‐165.
Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther. 2020;9(2):359‐374.
Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing‐remitting multiple sclerosis: a systematic review and network meta‐analysis. Autoimmun Rev. 2021;20(6):102826.
Correia I, Batista S, Galego O, et al. Long‐term effectiveness and safety of natalizumab in a Portuguese population. Int Immunopharmacol. 2017;46:105‐111.
Butzkueven H, Kappos L, Wiendl H, et al. Long‐term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real‐world data from the Tysabri observational program (TOP). J Neurol Neurosurg Psychiatry. 2020;91(6):660‐668.
Pontieri L, Blinkenberg M, Bramow S, et al. Ocrelizumab treatment in multiple sclerosis: a Danish population‐based cohort study. Eur J Neurol. 2022;29(2):496‐504.
Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA. Does Ocrelizumab limit multiple sclerosis progression? Current evidence from clinical, MRI, and fluid biomarkers. Neurotherapeutics. 2022;19:1216‐1228.
Pape K, Rolfes L, Steffen F, et al. Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real‐world propensity score‐matched study. Ther Adv Neurol Disord. 2022;15:17562864221142924.
Zhu C, Kalincik T, Horakova D, et al. Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation. JAMA Neurol. 2023;80(7):739‐748.
Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18(12):905‐922.
Granziera C, Derfuss T, Kappos L. Time to change the current clinical classification of multiple sclerosis? JAMA Neurol. 2023;80(2):128‐130.
Tur C, Carbonell‐Mirabent P, Cobo‐Calvo Á, et al. Association of Early Progression Independent of relapse activity with long‐term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023;80(2):151‐160.
Sharrad D, Chugh P, Slee M, Bacchi S. Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2023;78:104899.
Cagol A, Schaedelin S, Barakovic M, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 2022;79(7):682‐692.
Maggi P, Bulcke CV, Pedrini E, et al. B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. EBioMedicine. 2023;94:104701.
He A, Merkel B, Brown JWL, et al. Timing of high‐efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307‐316.
Iaffaldano P, Lucisano G, Caputo F, et al. Long‐term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574.
Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing‐remitting multiple sclerosis: data from 2 different National Strategies. JAMA Neurol. 2021;78(10):1197‐1204.
Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T. High‐efficacy therapies for treatment‐Naïve individuals with relapsing‐remitting multiple sclerosis. CNS Drugs. 2022;36(12):1285‐1299.
Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high‐efficacy disease‐modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269(3):1670‐1677.